BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 2890164)

  • 1. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
    Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S; Comaru-Schally AM; Milovanovic S; Schally AV
    Pancreas; 1993 Jan; 8(1):88-97. PubMed ID: 8093555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
    Paz-Bouza JI; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1987 Feb; 84(4):1112-6. PubMed ID: 2881296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
    Szende B; Zalatnai A; Schally AV
    Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
    Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally AV
    Breast Cancer Res Treat; 1992; 21(3):181-92. PubMed ID: 1355375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A; Paz-Bouza JI; Redding TW; Schally AV
    Prostate; 1988; 12(1):85-98. PubMed ID: 2894651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
    Zalatnai A; Schally AV
    Cancer Res; 1989 Apr; 49(7):1810-5. PubMed ID: 2564312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
    Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):248-52. PubMed ID: 6141560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.